OCSL

Business Context and Reporting Period

Oaktree Specialty Lending Corporation (OCSL) is a closed-end, externally managed Business Development Company (BDC) and Regulated Investment Company (RIC) focused on providing customized credit solutions to middle-market companies. This Form 10-Q covers the quarterly period ended December 31, 2019. The company is managed by Oaktree Capital Management, L.P.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total investment income decreased by $7.3 million (19.1%) compared to Q4 2018, primarily due to a $7.1 million decrease in interest income driven by lower Original Issue Discount (OID) accretion and lower LIBOR rates on floating-rate investments.
• Expense Increase: Net expenses increased by $2.2 million (10.3%) to $23.1 million. This was largely due to a $5.2 million reversal of previously accrued fee waivers following the expiration of a two-year contractual fee waiver period on October 17, 2019. This increase was partially offset by a $2.4 million decrease in interest expense.
• Profitability: Net investment income dropped significantly by $9.5 million (54.7%) to $7.84 million. However, the company recorded a net unrealized appreciation of $2.88 million, contrasting with a depreciation of $6.98 million in the prior year.
• Realized Gains: Net realized gains decreased to $3.29 million from $17.96 million in Q4 2018, reflecting fewer exit events.
• Liquidity: Cash and cash equivalents increased by $6.1 million to $21.5 million, supported by net borrowings of $63.0 million under the Credit Facility.

Guidance, Outlook, and Risks

• Portfolio Strategy: Management continues to reposition the portfolio, having reduced non-core investments by over $700 million since Oaktree became the adviser. Approximately $174 million in non-core investments remained as of December 31, 2019.
• LIBOR Transition: The company faces uncertainty regarding the phase-out of LIBOR by the end of 2021. Approximately 90.6% of the debt portfolio is floating-rate indexed to LIBOR. The company may need to renegotiate credit agreements and its Credit Facility.
• Fee Waiver Expiration: The expiration of the two-year fee waiver resulted in a one-time reversal of $5.2 million in expenses, impacting the current quarter's net expense ratio. Future quarters will reflect full fee accruals without this waiver.
• Subsequent Events: On January 31, 2020, the Board declared a quarterly distribution of $0.095 per share. Additionally, the company announced the redemption of 100% of its $75 million 2024 Notes on March 2, 2020.
• Non-Accrual Status: As of December 31, 2019, three investments were on cash or PIK non-accrual status, representing 3.35% of the debt portfolio at cost.

Investor Verification Checklist

• Fee Waiver Impact: Verify the sustainability of net investment income given the $5.2 million reversal of fee waivers, which artificially lowered expenses in Q4 2019.
• LIBOR Exposure: Assess the company's hedging or renegotiation strategy for the 90.6% of the debt portfolio tied to LIBOR ahead of the 2021 phase-out.
• Non-Core Assets: Monitor the progress of exiting the remaining $174 million in non-core investments to improve portfolio quality.
• Debt Redemption: Confirm the execution of the $75 million 2024 Notes redemption in March 2020 and its impact on future interest expense.
• Non-Accrual Investments: Review the specific portfolio companies on non-accrual status (Cenegenics, Dominion Diagnostics, PLATO Learning) for potential credit losses.